
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
The model in which young doctors acquired their medical skills by working unsupervised on poor patients at county hospitals is, fortunately, a thing of the past. Is today's model better?




